Composition of fast-acting insulin (variants)

MYPI2025003180A0Undetermined Publication Date: 2024-05-26OBSHCHESTVO S OGRANICHENNOJ OTVETABTVENNOSTJU GEROFARM
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
MYPI2025003180
Authority / Receiving Office
MY · MY
Patent Type
Applications
Current Assignee / Owner
Priority Date
2022-11-26
Filing Date
2023-11-24
Publication Date
2024-05-26

AI Technical Summary

Technical Problem

Fast-acting insulin compositions, such as insulin aspart, lispro, and glulisine, face challenges with reduced chemical and physical stability, particularly when containing nicotinamide, which accelerates absorption but negatively affects chemical stability, leading to increased impurities and potential aggregation issues.

Method used

Incorporating lysine and/or its salts, either alone or in combination with arginine and/or their salts, into the insulin compositions to enhance both chemical and physical stability, thereby reducing the formation of impurities and improving absorption profiles.

Benefits of technology

The use of lysine and/or arginine as stabilizers in rapid-acting insulin compositions significantly decreases impurity content and improves physical stability, maintaining therapeutic efficacy while minimizing adverse reactions and device clogging risks.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure PI2025003180_DRAWING_001
    Figure PI2025003180_DRAWING_001
Patent Text Reader

Abstract

The present invention relates to the field of pharmaceutical science and medicine, i.e., to the compositions of fast-acting insulin preparations. More specifically, the present invention relates to the compositions comprising a fast-acting insulin and an amino acid as a stabilizer, where the amino acid may be selected from lysine and / or salt thereof, or a combination of lysine and / or salt thereof with arginine and / or salt thereof. Compositions of the invention exhibit better chemical and physical stability compared to the closest prior art.
Need to check novelty before this filing date? Find Prior Art

Description

[0001] COMPOSITION OF RAPID-ACTING INSULIN (OPTIONS)

[0002] DESCRIPTION OF THE INVENTION

[0003] Field of technology to which the invention relates

[0004] The invention relates to the field of pharmaceuticals and medicine, namely to compositions of fast-acting insulin preparations. More specifically, the present invention relates to compositions containing fast-acting insulin and an amino acid as a stabilizer, which can be selected from lysine and / or its salt or a combination of lysine and / or its salt with arginine and / or its salt. The compositions according to the invention exhibit better chemical and physical stability compared to analogues.

[0005] State of the art

[0006] Insulin is a peptide hormone that regulates blood glucose levels in mammals by initiating a signaling cascade that accelerates glucose uptake and glycogen production upon binding to the insulin receptor. When insulin production is impaired, blood glucose levels increase (chronic hyperglycemia), which is the primary diagnostic feature of type 1 diabetes (T1D). However, when signal transmission from insulin receptors is impaired, even if the hormone is produced in sufficient quantities, type 2 diabetes (T2D) develops due to decreased tissue sensitivity to insulin (insulin resistance). The effectiveness of insulin in the treatment of diabetes mellitus, due to the ability of this hormone to lower blood glucose levels, has been proven over decades of its use in medical practice.However, the search for new approaches to the treatment of diabetes mellitus remains relevant due to the increasing number of cases of the disease and the need to take into account the individual characteristics and preferences of patients [1].

[0007] The development of fast-acting and ultra-fast-acting insulin analogues such as insulin aspart (NovoRapid®), insulin glulisine (Apidra®) and insulin lispro (Humalog®), which have a faster onset of action and a shorter duration of action, has become a significant step forward in the treatment of type 1 and type 2 diabetes. The formulations of the drugs NovoRapid®, Apidra®, Humalog® are the closest analogues of the compositions of the invention. In a neutral solution at a pharmaceutical concentration, insulin and its analogues are in the form of stabilized zinc-containing hexamers, which consist of three identical dimeric units. The delay in the action of insulin is largely associated with the time required for hexamers to dissociate into monomers and dimers capable of absorption [2,3].The first class of rapid-acting insulins (eg, insulin lispro and aspart) were developed based on amino acid mutations in the human insulin sequence that resulted in weakened self-association of insulin oligomers. For example, substitution of aspartic acid for proline at position B28 in insulin aspart reduces the tendency of the molecules to form hexamers, which is observed in solution of soluble human insulin. For this reason, insulin aspart is absorbed from subcutaneous fat much faster than soluble human insulin and is widely used for postprandial blood glucose control in patients with diabetes mellitus [4]. The molecular structure of insulin lispro is identical to that of human insulin except for positions 28 and 29 of the B-chain of the molecule, where lysine and proline are arranged in the reverse order (human insulin: B28ProB29Lys, lispro: B28LysB29Pro).The reverse arrangement of lysine and proline allows the lispro molecule to dissociate twice as fast. In the structure of insulin glulisine (3BLys29BGlu), the amino acid residue asparagine in the 3rd position of the B-chain of the human insulin molecule is replaced by lysine, and lysine in the 29th position of the B-chain is replaced by glutamine, which contributes to the stability of this drug in solution in the form of monomers and dimers [1].

[0008] Chemical and physical stability of insulin preparations is a prerequisite for ensuring the therapeutic effect of the preparations or the absence of side effects, and stability must be ensured both during storage during the shelf life of the preparations and during their use. Insulin compositions are manufactured, stored and used in vials, which requires their stability throughout the shelf life. Stable insulin compositions are especially necessary for use in delivery devices in which they are exposed to elevated temperatures close to body temperature and / or mechanical stress, such as, for example, injection pens and continuous infusion systems (using pumps).

[0009] It is known that fast-acting insulin analogues that are in monomeric or dimeric form have reduced physicochemical stability compared to hexamers [5], in particular, they form high-molecular impurities, and an increased tendency to aggregation (fibrillation), which manifests itself in the form of turbidity and sediment. High-molecular impurities (dimers, trimers, polymers) and aggregates not only reduce the administered dose of insulin, but can also provoke irritation or immune reactions in the patient. In addition, insoluble aggregates can clog and damage needles, cannulas and pump hoses in continuous infusion systems. To ensure the quality of insulin compositions, it is necessary to increase their chemical and physical stability.

[0010] There are insulin aspart medicinal products on the market (for example, NovoRapid® (Novo Nordisk A / S), RinFast® (GEROPHARM LLC). It has been shown that overall glycemic control can be improved by introducing the excipient nicotinamide into the product, which can accelerate the absorption of insulin aspart, compared to insulin aspart preparations without nicotinamide. In particular, it has been shown that Fiasp® (containing nicotinamide) compared to NovoRapid® (not containing nicotinamide) provided improved overall glycemic control and better postprandial glycemic control without increasing the overall risk of severe or confirmed hypoglycemia in patients with type 1 and type 2 diabetes. The pharmacokinetic characteristics of the rapid-acting insulin aspart Fiasp® can better reproduce rapid endogenous secretion prandial insulin and thus improve postprandial glycemic control compared with insulin aspart [6].

[0011] Nicotinamide has the ability to accelerate the absorption of insulin (WO 91 / 09617), including insulin aspart (WO / 9610417), but has a negative effect on chemical stability - increases the content of impurities (RU2533217). The chemical stability of the composition of the medicinal product (MP) "Fiasp®" is increased by introducing arginine into the composition, which is reflected in a decrease in the content of dimers and polymers, deamidated insulins during storage (RU2533217). The composition of the MP "FIASP®" is another of the closest analogues of the present invention.

[0012] Patent RU2533217 shows (example 2) that the addition of arginine to compositions containing insulin aspart with nicotinamide reduces the amount of formed degradation products, especially high-molecular protein and deamidated forms, but at the same time reduces physical stability, measured as the delay time in the thioflavin T assay; with an increase in the concentration of arginine, physical stability decreases even more. In a report on a small (n = 37) 6-week study of the tendency of infusion systems to clog and malfunction, no cases of clogging of infusion systems were noted with either FIASP (25 subjects) or insulin aspart (12 subjects). However, unexplained hyperglycemia and premature change of the infusion set were more common with the use of FIASP compared to the use of insulin aspart [7].

[0013] Thus, at present, there remains a need for compositions of fast-acting insulins that have increased chemical stability and at the same time acceptable physical stability. The above-mentioned technical problem is especially relevant for compositions of fast-acting insulins, such as, for example, insulin aspart, insulin lispro or insulin glulisine, which are characterized by worse stability compared to hexameric forms of insulin, as well as for compositions containing nicotinamide, which is capable of accelerating the absorption of insulin, but at the same time negatively affects the chemical stability of insulin.

[0014] ESSENCE OF THE INVENTION

[0015] The authors of the present invention have unexpectedly discovered that fast-acting insulin compositions containing an amino acid, which is lysine and / or its salt or a combination of lysine and / or its salt with arginine and / or its salt, as a stabilizer have improved chemical and physical stability compared to insulin compositions without added amino acids, as well as to insulin compositions containing the amino acid arginine as a stabilizer.

[0016] Thus, the present invention relates to compositions with improved chemical and physical stability, containing fast-acting insulin and an amino acid, which is lysine or its salt, or a combination of lysine or its salt with arginine or its salt.

[0017] The present invention relates to compositions for lowering blood glucose levels in a subject, comprising a fast-acting insulin and an amino acid that is lysine or a salt thereof, or a combination of lysine or a salt thereof with arginine or a salt thereof.

[0018] In preferred embodiments of the invention, the insulin is insulin aspart, insulin lispro and insulin glulisine.

[0019] The insulin glulisine compositions optionally further comprise methionine. The concentration of rapid-acting insulin in the compositions of the invention is from about 0.2 mM to 2.0 mM (from about 33 U / mL to about 333 U / mL), preferably from about 0.3 mM to 1.2 mM (from about 50 U / mL to about 200 U / mL), even more preferably 0.6 mM (100 U / mL).

[0020] In one embodiment of the present invention, the compositions have a pH of 6.5 to 8.5. In another embodiment of the present invention, the compositions have a pH of 6.6 to 7.4. In one embodiment, the pH is 7, 7.3, 7.4, or 7.5.

[0021] The compositions of the invention containing insulin aspart additionally, but not necessarily, contain a nicotinic acid compound selected from nicotinamide (niacinamide), nicotinic acid (niacin) and / or a salt thereof and / or any combination thereof, the preferred nicotinic acid compound being nicotinamide. The concentration of nicotinamide or another nicotinic acid compound in the compositions of the invention containing insulin aspart is from about 1 mM to about 200 mM.

[0022] The concentration of lysine and / or its salt or the total concentration of lysine and / or its salt in combination with arginine and / or its salt is from about 1 mM to about 100 mM.

[0023] In compositions containing a combination of lysine and / or its salt and arginine and / or its salt, the molar ratio of amino acids is from 4000:1 to 1:4000, respectively, said range including each integer ratio, such as 100:1, 99:1, 98:1, etc. In one preferred embodiment, the molar ratio of lysine to arginine is 1:1, 4:5, 5:4, 6:4; 5:2 or 2:5.

[0024] The compositions of the invention may additionally contain protease inhibitor(s), metal ions, buffer systems, pH regulators, preservative(s), isotonic agent(s), chelating agent(s), stabilizers and surfactants.

[0025] In one embodiment, the compositions of the invention are aqueous compositions, i.e. compositions containing water and are solutions or suspensions.

[0026] The compositions of the present invention can be used for the treatment or prevention of hyperglycemia, type 2 diabetes mellitus, impaired glucose tolerance, type 1 diabetes mellitus.

[0027] In one preferred embodiment, the compositions of the invention are administered parenterally. Parenteral administration may be performed by subcutaneous, intramuscular, intraperitoneal or intravenous injection using a syringe, possibly a syringe pen. Alternatively, parenteral administration may be performed using an infusion pump.

[0028] Thus, the present invention also relates to injectable insulin preparations containing the compositions of the present invention.

[0029] TERMS AND DEFINITIONS

[0030] The term "human insulin" as used herein refers to a human hormone whose structure and properties are well known. Insulin is a polypeptide of 51 amino acids, which is divided into 2 amino acid chains: chain A, consisting of 21 amino acids, and chain B, consisting of 30 amino acids. The chains are linked together by 2 disulfide bridges. Insulin preparations have been used to treat diabetes mellitus for many years, and recently not only insulins of natural origin have been used, but also insulin derivatives and analogs.

[0031] An "insulin analog" as referred to herein is a polypeptide derived from the primary structure of natural insulin, such as human insulin, by mutation. One or more mutations are obtained by deleting and / or replacing at least one amino acid residue occurring in natural insulin and / or by adding at least one amino acid residue. Mutations in the insulin molecule are designated by indicating the chain (A or B), position, and three-letter code for the amino acid replacing the native amino acid.

[0032] The term "rapid-acting insulin" or "short-acting insulin" refers to insulin analogues and / or insulin derivatives that have an onset of action within 5-15 minutes and a duration of action of 3-4 hours. Examples of rapid-acting insulins include, but are not limited to, insulin aspart, insulin lispro, and insulin glulisine.

[0033] The terms "monomeric human insulin analogue", "monomeric insulin analogue" are well known in the art and generally refer to rapidly acting analogues of human insulin. These include, for example, insulin lispro (Humalog®), insulin aspart (NovoRapid®) and insulin glulisine (Apidra®).

[0034] The content of rapid-acting insulin in the compositions of the invention may be in the range of about 0.2 mM to about 2.0 mM (about 33 to about 333 international units (IU) / mL), preferably in the range of about 0.3 mM to about 1.2 mM (about 50 to about 200 IU / mL), particularly preferably at a concentration of 0.6 mM (100 U / mL), in injection preparations. However, for other parenteral administration purposes, the content of insulin compound may be higher.

[0035] In this context, the unit "IU" corresponds to 6 nmol.

[0036] The term "rapid-acting insulin composition" as used herein means a product comprising a monomeric insulin analogue and an amino acid selected from lysine and / or a salt thereof or a combination of lysine and / or a salt thereof with arginine and / or a salt thereof. Preferably, the monomeric insulin analogue in the composition is insulin aspart, insulin lispro and insulin glulisine. The insulin aspart composition of the present invention may optionally comprise a nicotinic acid compound selected from nicotinamide (niacinamide), nicotinic acid (niacin) and / or a salt thereof and / or any combination thereof.The rapid-acting insulin composition may optionally also contain other excipients such as preservatives, chelating agents, isotonic agents, fillers, stabilizers, antioxidants, polymers and surfactants, metal ions, oil carriers and proteins (e.g. human serum albumin, gelatin or proteins), pH regulators, and the rapid-acting insulin composition can be used to treat, prevent or reduce the severity of a disease or disorder by administering said insulin preparation to a human. Thus, the rapid-acting insulin composition of the present invention can be called a "pharmaceutical composition".

[0037] The terms "protein preparation", "protein composition" and "protein" may be used interchangeably within the framework of the present invention and mean any medicinal product containing as an active substance a molecule consisting of polypeptide chains consisting of amino acid residues linearly linked by a peptide bond, alone or in combination with other compounds. An insulin composition or insulin, for example, are special cases and are covered by these terms.

[0038] The terms "lysine" and "arginine" refer to amino acids and include the D- and L-enantiomers, as well as mixtures thereof. The term also includes any pharmacologically acceptable salts of lysine and arginine. Lysine and arginine readily form salts, such as hydrochlorides. The term "nicotinic acid compound" includes nicotinamide (niacinamide), nicotinic acid (niacin), and / or their salts, and / or any combination thereof.

[0039] The buffer may be selected from the group consisting of sodium acetate, sodium carbonate, citrate, sodium dihydrogen phosphate, sodium hydrogen phosphate, sodium phosphate, as well as tris(hydroxymethyl)aminomethane, bicine, tricine, malic acid, succinate, maleic acid, fumaric acid, tartaric acid, aspartic acid, or mixtures thereof, but not limited to them. Each of these specific buffers or each of their combinations is an alternative embodiment of the invention.

[0040] The rapid-acting insulin composition of the present invention may also contain other ingredients commonly used in insulin preparations, such as zinc complexing agents.

[0041] Isotonic agents such as glycerol, mannitol, sodium chloride, dextrose, etc. may also be present in the compositions of the present invention. An isotonic agent is a physiologically acceptable compound that imparts suitable tonicity to the composition in order to prevent diffusion of water through cell membranes in contact with the pharmaceutical composition.

[0042] The composition of the present invention may contain a pharmaceutically acceptable preservative. The preservative present in the composition of the present invention may be phenol, m-cresol, methylparaben, etc.

[0043] The composition of the present invention may also contain a chelating agent. The use of chelating agents in pharmaceutical preparations is well known to those skilled in the art.

[0044] The composition of the present invention may also contain a stabilizer. The term "stabilizer" as used herein refers to chemicals added to pharmaceutical preparations containing a polypeptide to stabilize it, i.e. to increase the shelf life and / or the time of use of such preparations.

[0045] The term "surfactant" as used herein refers to any molecule or ion that consists of a water-soluble (hydrophilic) portion, a head, and a fat-soluble (lipophilic) segment. Surfactants concentrate preferentially at the interface with the hydrophilic portion oriented toward the water (hydrophilic phase) and the lipophilic portion toward the oil or hydrophobic phase (i.e., glass, air, oil, etc.). Surfactants reduce the surface tension of a liquid. They are also known as amphipathic compounds. The term "detergent" is generally synonymous with the term "surfactant." The use of surfactants in pharmaceuticals is well known to those skilled in the art. These include, for example, polysorbate 20, polysorbate 80, poloxamer 188, etc. These substances are described as excipients in current pharmacopoeias (USP, EP).

[0046] As used herein, the term "stability" refers to the chemical and physical stability of the monomeric insulin analog compositions.

[0047] The term "chemical stability" of a protein composition (protein preparation) and / or protein, as used in the present description of the invention, refers to changes in the covalent structure of the protein, leading to the formation of chemical degradation products with potentially lower biological activity and / or potentially enhanced immunogenic properties compared to the native structure of the protein. Different chemical degradation products can be formed depending on the type and nature of the native protein and the external factors to which the protein is exposed. An increase in the amount of chemical degradation products is often observed during storage and use of the protein preparation.Most proteins are prone to deamidation, other degradation pathways involve the formation of high molecular weight products in which two or more protein molecules are covalently linked to each other through transamidation and / or disulfide interactions, resulting in the formation of covalently linked dimeric, oligomeric and polymeric degradation products [8]. Another option for chemical degradation is oxidation (e.g. of methionine residues). The chemical stability of a protein preparation and / or protein can be assessed by measuring the amount of chemical degradation products at various time points after exposure to different environmental conditions (the formation of degradation products can often be accelerated, e.g. by increasing the temperature).The amount of each individual degradation product is often determined by separating the degradation products based on molecular size and / or charge using various chromatographic techniques (e.g., size exclusion liquid chromatography (SEC-HPLC) and / or reversed-phase high-performance liquid chromatography (RP-HPLC)). Since high molecular weight protein products are potentially immunogenic and biologically inactive, high molecular weight protein levels should be low.

[0048] Physical instability of a protein composition (protein preparation) and / or protein may be caused by aggregation of protein molecules to form higher order polymers or even precipitates. Physical denaturation of insulin is known as fibrillation. In the fibrillar state, the elongated peptide chains are arranged parallel or antiparallel and hydrogen bonded to each other, forming the so-called P-structure or P-pleated sheets. Fibrils usually represent the lowest energy state of the protein, and regeneration of the protein from this state to the native state of correctly folded protein is possible only in a highly alkaline environment. Insulin fibrils appear as gels or precipitates. Factors that promote an increase in the rate of fibril formation include exposure to thermomechanical stress and / or interaction with phase boundaries and hydrophobic surfaces. Fibril formation is believed to occur due to insulin monomerization.Monomeric insulin analogues that readily dissociate from the hexameric unit to the monomeric form are more prone to fibril formation than human insulin.

[0049] Physical stability can be assessed by methods well known in the art, such as measuring turbidity (optical density). Turbidity results from aggregation or precipitation of proteins or complexes in the compositions.

[0050] The physical stability of aqueous protein preparations can also be assessed using a spectroscopic agent or probe of the protein conformational state. The probe is preferably a small molecule that preferentially binds to non-native conformers of the protein. One example of a small molecule spectroscopic probe of protein structure is thioflavin T. Thioflavin T is a fluorescent dye that is widely used to detect amyloid fibrils. In the presence of fibrils and possibly also other protein conformations, thioflavin T produces a new excitation maximum at about 445 nm and enhances the emission at about 485 nm when bound to the fibrillar form of the protein. Unbound thioflavin T is essentially non-fluorescent at these wavelengths.

[0051] "Stable composition" is a composition in which the degree of protein aggregation and impurity content are within normal limits and do not increase over time. The term "aqueous preparation" refers to a preparation containing water. The terms "aqueous solution" and "aqueous suspension" refer, respectively, to a solution or suspension containing water. Aqueous suspensions may contain the active compounds in admixture with excipients suitable for the manufacture of aqueous suspensions.

[0052] EXAMPLES

[0053] Example 1. Preparation of compositions according to the invention containing insulin aspart

[0054] In one embodiment, the pharmaceutical compositions of the present invention are prepared in the form of aqueous solutions. Table 1 shows the qualitative and quantitative composition of some of the prepared compositions. The compositions of the invention include, but are not limited to, compositions 4-17 shown in Table 1. The composition of composition 1 corresponds to the composition of one of the closest analogues of the invention, the composition of the drug "Fiasp®". Composition 2 reproduces the composition of composition 1, except that it does not contain L-arginine hydrochloride. Composition 3 corresponds to the composition of composition 1, except that it does not contain nicotinamide. Composition 4 reproduces the composition of composition 3, but with the addition of L-lysine hydrochloride instead of L-arginine hydrochloride. Composition 5 reproduces the composition of composition 3 with the addition of a combination of L-lysine and L-arginine.

[0055] The method for producing the compositions comprises: a) preparing a solution of insulin aspart by dissolving it in water or buffer; b) preparing a solution of zinc salt by dissolving it in water or buffer; c) preparing a solution of preservatives (phenolic compounds) by dissolving them in water or buffer; d) preparing a solution of an isotonic agent by dissolving it in water or buffer; d) preparing a solution of nicotinamide and / or another nicotinic acid compound (if present in the composition) by dissolving in water or buffer; e) preparing a solution of lysine and / or arginine by dissolving amino acids and / or their salts in water or buffer; g) mixing solution a) and solutions b), c), d), e) if present, and f) in accordance with the composition of the compositions given in Table 1; h) bringing the pH of mixture g) to a value of 6.6-7.4, followed by sterilizing filtration. i) aseptic filling of cartridges with the prepared compositions.The compositions of the invention can be prepared by any other method.

[0056] Table 1. Qualitative and quantitative composition of the compositions according to the invention containing insulin aspart

[0057]

[0058] Example 2. Analysis of the physical and chemical stability of compositions according to the invention containing insulin aspart

[0059] The chemical stability was determined for compositions 1-17, obtained according to Example 1, after thermostatting the aseptically filled cartridges at a temperature of 40°C for 1 and 2 weeks.

[0060] Determination of insulin aspart-related impurities was carried out by HPLC with UV detection on a column filled with octadecyl silica gel with a particle size of 5 μm and a pore size of 300 A with a mobile phase flow rate of 1.0 ml / min and a wavelength of 214 nm.

[0061] Elution was carried out in a gradient mode with a mobile phase consisting of the following components: mobile phase A (MP A): acetonitrile: buffer solution with pH 3.4 (1.4% solution (w / V) of anhydrous sodium sulfate, 0.13% solution (V / V) of concentrated orthophosphoric acid, 2 M sodium hydroxide to pH 3.4 ± 0.05) 10:90 (V / V); mobile phase B (MP B): acetonitrile: water 50:50 (V / V).

[0062] The amount of impurity B28IsoAsp, deamidated (B3iso, A21Asp, B3Asp) and other related impurities was determined by the method of internal normalization by the absorption area of ​​the corresponding peaks, measured as a percentage of the sum of the areas of the peaks eluted after nicotinamide and preservatives.

[0063] The amount of high-molecular protein (HMP) was determined by size-exclusion liquid chromatography on a column packed with hydrophilic silica gel for chromatography with a particle size of 10 μm and a pore diameter of 125 A. A mixture of acetonitrile: glacial acetic acid: 0.1% arginine solution (20:15:65) (V / V / V) was used as an eluent. Elution was performed in the isocratic mode at a flow rate of 0.5 ml / min at a detection wavelength of 276 nm. The HMP content was determined by the method of internal normalization based on the sum of the absorption areas of all peaks with retention times shorter than that of the insulin aspart monomer peak. Peaks with retention times longer than that of the insulin aspart monomer peak (nicotinamide and preservatives) were not taken into account in the calculation.

[0064] To assess the physical stability of the protein compositions, an analysis was performed for the tendency to form fibrils using Thioflavin-T (ThT). The selected method is described in the literature, for example, in patent RU2533217. The tendency to form fibrils was determined for compositions 1, 3 - 17, given in Example 1, as well as for the finished form of the original medicinal product "Fiasp". The composition of the medicinal product "Fiasp" was reproduced in composition 1. The analysis was performed immediately after the preparation of the compositions.

[0065] Preparation of solutions

[0066] Stock solution of thioflavin

[0067] Take an exact weighed portion of the dry Thioflavin T reagent, dissolve in methanol to a thioflavin concentration of 1 mg / ml (which corresponds to 3.14 mM). Mix the solution thoroughly on a vortex, store protected from light at a temperature of + 2 - 8 °C for up to 6 months.

[0068] Working solution of thioflavin

[0069] Prepare a working solution with a thioflavin concentration of 200 μM in purified water. The volume of the stock solution to purified water is calculated in the proportion 1:14.7. Use freshly prepared.

[0070] Aliquots of 100 μl of samples in triplicates are placed in a black 96-well plate; purified water is used as a control sample. 10 μl of the working solution of thioflavin were added to all wells. When filling the plate, the outer wells are avoided (see Fig. 1). The plate is sealed with transparent film and placed in a CLARIOstar multimodule plate reader (B MG, Germany). The fluorescent signal is detected every 20 minutes for 12 hours at a wavelength of 445 / 485 nm. Between readings, the plate is mixed at 700 rpm. Mixing and detection are carried out at a temperature of 37 °C.

[0071] Based on the measurement results, graphs of the signal dependence in relative fluorescence units on time in hours are constructed for each sample. A 4-parameter dependence is used for analysis.

[0072] The graph is used to determine T1 / 2max - the time during which half of the analyzed sample aggregates. If the graph is obtained in the form of a straight line at the zero value level, the sample is considered not prone to aggregation; in other cases, the degree of proneness to aggregation is estimated by T 1 / 2max.

[0073] Along with T 1 / 2 max, the ThT fluorescence curve visually determines the delay time as the time point at which ThT fluorescence differs from the background level.

[0074] Table 2 shows the results of determining the chemical and physical stability of compositions 1, 3-17 containing insulin aspart.

[0075] Table 2. Data on physical and chemical stability of compositions 1,

[0076] 3-17, containing insulin aspart, obtained according to example 1.

[0077] * Original drug "Fiasp"; **N / A - "according to analysis", not analyzed.

[0078] Based on the study of the chemical and physical stability of insulin aspart compositions prepared using both a phosphate buffer and a Tris buffer, it was unexpectedly discovered that when adding lysine and / or its salt and / or a combination of lysine and / or its salt with arginine and / or its salt, the amount of impurities after 2 weeks of storage at 40°C in the compositions according to the invention is substantially and reliably less than in the prototype, while physical stability is also improved compared to the prototype.

[0079] Nicotinamide used in the composition without added amino acids (composition 2) has a negative effect on chemical stability during storage. Arginine in composition 1, reproducing the drug "FIASP", prevents chemical degradation, one of the reasons for which is the addition of nicotinamide, which is reflected in a decrease in the content of VMB, deamidated insulins after 2 weeks of storage at 40 ° C compared to the content of impurities in composition 2 that does not contain arginine. When arginine in composition 1 is replaced by an equimolar amount of lysine (composition 6), the content of impurities is significantly reduced, an increase in the lysine concentration to 100 mM contributes to an even greater decrease in the amount of impurities. A lysine concentration of more than 100 mM is undesirable due to deterioration in the physical stability of the compositions. The lowest amount of impurities is noted when using a combination of lysine and arginine (composition 10).

[0080] Similar results were obtained for compositions using Tris buffer (compositions 11-17), with better chemical stability noted for compositions prepared using Tris buffer compared to similar compositions prepared using phosphate buffer.

[0081] For compositions that do not contain nicotinamide (compositions 3-5), a significant advantage of stabilization with lysine or a combination of lysine and arginine was also shown compared to stabilization with arginine.

[0082] Example 3. Preparation of compositions according to the invention containing insulin glulisine

[0083] In one embodiment, the pharmaceutical compositions of the present invention are prepared in the form of aqueous solutions. Table 3 shows the qualitative and quantitative composition of some of the prepared compositions. The compositions of the invention include, but are not limited to, compositions 2-7 shown in Table 3. The composition of composition 1 corresponds to the composition of the original drug "Apidra®", solution for subcutaneous administration, 100 U / ml. The compositions of compositions 2-7 reproduce the composition of the original drug with the addition of L-lysine hydrochloride or a combination of L-lysine hydrochloride and L-arginine hydrochloride.

[0084] The method for producing the compositions comprises: a) preparing a solution of insulin glulisine by dissolving it in water or buffer; b) preparing a solution of a preservative by dissolving it in water or buffer; c) preparing a solution of an isotonic agent by dissolving it in water or buffer; d) preparing a solution of a surfactant by dissolving it in water or buffer; d) preparing a solution of lysine and / or a combination of lysine with arginine by dissolving amino acids and / or their salts in water or buffer; e) mixing solution a) and solutions b), c), d), e) in accordance with the composition of the compositions given in Table 3; g) bringing the pH of mixture e) to 7.3, followed by sterilizing filtration. h) aseptic filling of cartridges with the prepared compositions.

[0085] The compositions of the invention can be prepared by any other method.

[0086] Table 3. Qualitative and quantitative composition of the compositions of the invention containing insulin glulisine

[0087] Example 4. Analysis of the physical and chemical stability of compositions according to the invention containing insulin glulisine

[0088] The chemical stability was determined for compositions 1–7, obtained according to Example 3, after thermostatting the aseptically filled cartridges at a temperature of 40°C for 1 and 2 weeks.

[0089] Determination of insulin glulisine-related impurities was carried out by HPLC with UV detection on a column filled with octadecyl silica gel with a particle size of 5 μm and a pore size of 100 A with a mobile phase flow rate of 1.0 ml / min and a wavelength of 214 nm.

[0090] Elution was carried out in a gradient mode with a mobile phase consisting of the following components: mobile phase A (MP A): acetonitrile: buffer solution with pH 2.3 (0.1 M sodium sulfate solution, orthophosphoric acid qs up to pH 2.3) 10:90 (V:V); mobile phase B (MP B): acetonitrile: buffer solution with pH 2.3 (0.1 M sodium sulfate solution, orthophosphoric acid qs up to pH 2.3) 50:50 (V:V).

[0091] The amount of impurity A21 - deamidoinsulin glulisine and other related impurities was determined by the method of internal normalization by the absorption area of ​​the corresponding peaks, measured as a percentage of the sum of the areas of the peaks eluted after metacresol.

[0092] The amount of VMB in compositions containing insulin glulisine was determined using a method similar to the determination of VMB in compositions containing insulin aspart (see Example 2). The VMB content was determined using the internal normalization method based on the sum of the absorption areas of all peaks with retention times shorter than that of the insulin glulisine monomer peak. Peaks with retention times longer than that of the insulin glulisine monomer peak (meta-cresol peak) were not taken into account in the calculation.

[0093] The physical stability of compositions containing insulin glulisine was assessed in a similar manner to the physical stability of compositions containing insulin aspart (see Example 2).

[0094] Table 4 shows the results of stability determination of compositions containing insulin glulisine.

[0095] Table 4. Data on the chemical stability of compositions 1-7 containing insulin glulisine, obtained according to Example 3.

[0096] * Original medicinal product "Apidra®"

[0097] Based on the study of the chemical and physical stability of compositions 1-7 containing insulin glulisine, it was unexpectedly discovered that when adding lysine and / or its salt and / or a combination of lysine and / or its salt with arginine and / or its salt, the amount of impurities after 2 weeks of storage at 40°C in the compositions according to the invention is substantially and reliably less than in the prototype, while physical stability is also improved compared to the prototype.

[0098] Increasing the lysine concentration to 100 mM helps reduce the amount of impurities. Lysine concentrations over 100 mM are undesirable due to deterioration of the physical stability of the compositions. The lowest amount of impurities was observed when using a combination of lysine and arginine.

[0099] Example 5. Preparation of compositions according to the invention containing insulin lispro

[0100] In one embodiment, the pharmaceutical compositions of the present invention are prepared in the form of aqueous solutions. Table 5 shows the qualitative and quantitative composition of some of the prepared compositions. The compositions of the invention include, but are not limited to, compositions 2-8 shown in Table 5. The composition of composition 1 corresponds to the composition of the original drug "Humalog", solution for intravenous and subcutaneous administration, 100 U / ml. Compositions 2-7 reproduce the composition of the original drug with the addition of L-lysine hydrochloride or a combination of L-lysine hydrochloride and L-arginine hydrochloride.

[0101] The method for producing the compositions comprises: a) preparing an insulin solution by dissolving it in water or a buffer; b) preparing a zinc solution by dissolving zinc oxide in a dilute hydrochloric acid solution; c) preparing a preservative solution by dissolving it in water or a buffer; d) preparing an isotonic agent solution by dissolving it in water or a buffer; d) preparing a lysine and / or arginine solution by dissolving amino acids and / or their salts in water or a buffer; e) mixing solution a) and solutions b), c), d), e) in accordance with the composition of the compositions given in Table 1; g) bringing the pH of mixture e) to 7-8, followed by sterilizing filtration. h) aseptic filling of cartridges with the prepared compositions.

[0102] The compositions of the invention can be prepared by any other method.

[0103] Table 5. Qualitative and quantitative composition of the compositions according to the invention containing insulin lispro Example 6. Analysis of the physical and chemical stability of the compositions of the invention containing insulin lispro

[0104] The chemical stability was determined for compositions 1-8 (compositions containing insulin lispro), obtained according to Example 5, after thermostatting the aseptically filled cartridges at a temperature of 40° C for 1 and 2 weeks.

[0105] The impurity A21-desamidoinsulin lispro and other insulin lispro-related impurities were determined by HPLC with UV detection on a column filled with octadecyl silica gel with a particle size of 3.5 μm. The mobile phase used as an eluent consisted of the following components: mobile phase A (MP A): sodium perchlorate buffer solution pH 2.2; mobile phase B (MP B): acetonitrile for chromatography.

[0106] Elution was carried out in gradient mode with a mobile phase flow rate of 0.9 ml / min and a detection wavelength of 214 nm.

[0107] The amount of impurity A21 desamidoinsulin lispro and other related impurities was determined by the method of internal normalization by the absorption area of ​​the corresponding peaks, measured as a percentage of the sum of the areas of the peaks eluted after metacresol.

[0108] The amount of VMB in compositions containing insulin lispro was determined using a method similar to the determination of VMB in compositions containing insulin aspart or insulin glulisine (see Example 2). The VMB content was determined by the internal normalization method based on the sum of the absorption areas of all peaks with retention times shorter than that of the insulin lispro monomer peak. Peaks with retention times longer than that of the insulin lispro monomer peak (meta-cresol peak) were not taken into account in the calculation.

[0109] The physical stability of compositions containing insulin lispro was assessed in a similar manner to the physical stability of compositions containing insulin aspart (see Example 2).

[0110] Table 6 shows the results of determining the chemical and physical stability of compositions containing insulin lispro.

[0111] Based on the study of the chemical and physical stability of compositions 1-8 containing insulin lispro, it was unexpectedly discovered that when adding lysine and / or its salt and / or a combination of lysine and / or its salt with arginine and / or its salt, the amount of impurities after 2 weeks of storage at 40° C in the compositions according to the invention was substantially and reliably less than in the prototype, while physical stability was also improved compared to the prototype.

[0112] Increasing the lysine concentration to 100 mM helps reduce the amount of impurities. Lysine concentrations over 100 mM are undesirable due to deterioration of the physical stability of the compositions. The lowest amount of impurities was observed when using a combination of lysine and arginine.

[0113] Table 6. Data on the physical and chemical stability of compositions 1 - 8 containing insulin lispro, obtained according to Example 5.

[0114] * Original LP "Humalog" Bibliography:

[0115] 1. Selivanova O. M., Grishin S. Yu., Glyakina A. V., et al. Analysis of insulin analogs and strategy for their further development. Advances in Biological Chemistry. 2018, 58: 313–346. . Brange J., Owens DR, Kang S., Volund A. Monomeric Insulins and Their Experimental and Clinical Implications. Diabetes Care. 1990, 13(9), 923–

[0116] 954.doi:10.2337 / diacare.13.9.923

[0117] 3. Schlein M. Insulin Formulation Characterization - the Thio flavin T Assays. AAPS Journal. 2017, 19(2): 397 - 408. . Instructions for use of the medicinal product for medical use "Fiasp". URL: http: / / grls.rosminzdrav.ru (date of access 30.08.22).

[0118] 5. Brange J. Stability of Insulin. Kluwer Academic Publisher. 1994, 18-23.

[0119] 6. Paquot N., Scheen A. J. Faster aspart insulin (FIASP®). Revue Medicale de Liege. 2018; 73 (4): 211-215. . Muchmore D. B. Pump Users Clamor for Faster Insulin: Is Fast-Acting Insulin Aspart Ready for Them? Journal of Diabetes Science and Technology. 2018; 12(1): 152— 154. doi:10.1177 / 1932296817750166

[0120] 8. Ahem T. J., Manning M. C. Stability of Protein Pharmaceuticals. Plenum Press. New York. 1992.

Claims

CLAUSES OF THE INVENTION 1. A composition for lowering blood glucose levels in a subject, comprising fast-acting insulin and an amino acid that is lysine or a salt thereof, or a combination of lysine or a salt thereof with arginine or a salt thereof.

2. The composition according to claim 1, wherein the fast-acting insulin is selected from the group comprising insulin aspart (B28Asp), insulin lispro (B28LysB29Pro), insulin glulisine (3BLys29BGlu).

3. The composition according to i. 2, wherein the rapid-acting insulin is insulin aspart (B28Asp).

4. The composition according to claim 1, wherein the amino acid is lysine or a salt thereof.

5. The composition according to claim 1, wherein the amino acid is a combination of lysine or its salt with arginine or its salt.

6. The composition according to claim 3, wherein the amino acid is lysine or a salt thereof.

7. The composition according to paragraph 3, in which the amino acid is a combination of lysine and arginine.

8. The composition according to i. 2, wherein the fast-acting insulin is glulisine (3BLys29BGlu).

9. The composition according to claim 8, which additionally contains methionine.

10. The composition of claim 1, wherein insulin is present in an amount of from about 0.2 mM (33 U / ml) to about 2 mM (333 U / ml).

11. The composition of claim 1, wherein insulin is present in an amount of from about 0.3 mM (50 U / ml) to about 1.2 mM (200 U / ml).

12. The composition according to i.10 or i.11, characterized in that the insulin is insulin aspart and the composition additionally contains a nicotinic acid compound.

13. The composition according to item 12, characterized in that it contains nicotinamide as a nicotinic acid compound.

14. The composition according to I.13, containing from about 1 mM to about 200 mM nicotinamide.

15. The composition according to claim 10 or claim 11, comprising from about 1 mM to about 100 mM lysine or a salt thereof. 25 16. The composition according to claim 10 or claim 11, containing from about 1 mM to about 100 mM of a combination of lysine or a salt thereof with arginine or a salt thereof.

17. The composition according to claim 1, further comprising a metal ion, preservative(s), isotonic agent(s) and stabilizer(s), buffer(s) and acidity regulators.

18. The composition according to claim 1 for use in the treatment or prevention of hyperglycemia, type 2 diabetes mellitus, impaired glucose tolerance, type 1 diabetes mellitus.

19. An injectable insulin preparation for lowering blood glucose levels in a subject, comprising a composition according to any one of paragraphs 1-17.